Orkambi: Medgend

Orkambi FDA Approved Drugs

ORKAMBI [Ivacaftor^{C₂₄H₂₈N₂O₃} : Lumacaftor^{C₂₄H₁₈F₂N₂O₅}]

125mg : 100mg (oral tablet)

125mg : 200mg (oral tablet)

Vertex Pharms Inc^{Sep 28, 2016}

Method of treating a patient having cystic fibrosis using ivacaftor and lumacaftor.
Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using a dosage unit as defined in claim 1 of u.s. patent no. 9,192,606.
Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using ivacaftor and form i lumacaftor.
Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using ivacaftor and lumacaftor.
Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using the dosage unit of claim 1 of u.s. patent no. 8,716,338.
Method of treating cystic fibrosis in patients who are homozygous for the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
Method of treating cystic fibrosis in patients who have the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene..
Method of treating cystic fibrosis using n-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide and 3-(6-(1-2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid.
Method of treating cystic fibrosis.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.